This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Jul;40(2):218-20.

doi: 10.1111/apt.12828.

Letter: infliximab vs. adalimumab in treating ambulatory perianal fistulising Crohn's disease

A Tursi¹, W Elisei, M Picchio, C Zampaletta, R Faggiani, G Brandimarte

Affiliations

PMID: 24946069
DOI: 10.1111/apt.12828

Comment

Letter: infliximab vs. adalimumab in treating ambulatory perianal fistulising Crohn's disease

A Tursi et al. Aliment Pharmacol Ther. 2014 Jul.

. 2014 Jul;40(2):218-20.

doi: 10.1111/apt.12828.

Authors

A Tursi¹, W Elisei, M Picchio, C Zampaletta, R Faggiani, G Brandimarte

Affiliation

¹ Gastroenterology Service, ASL BAT, Andria, BT, Italy. antotursi@tiscali.it.

PMID: 24946069
DOI: 10.1111/apt.12828

No abstract available

PubMed Disclaimer

Comment on

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.
Panaccione R, Colombel JF, Sandborn WJ, D'Haens G, Zhou Q, Pollack PF, Thakkar RB, Robinson AM. Panaccione R, et al. Aliment Pharmacol Ther. 2013 Nov;38(10):1236-47. doi: 10.1111/apt.12499. Epub 2013 Sep 22. Aliment Pharmacol Ther. 2013. PMID: 24134498 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information